NTT and FURUNO ELECTRIC: GPS Time Synchronization with World-Class Accuracy Using a Few Selected Satellites
Nippon Telegraph and Telephone Corporation (TOKYO: 9432) (NTT, Head office: Chiyoda-ku Tokyo; President & CEO: Jun Sawada) and FURUNO ELECTRIC CO., LTD. (TOKYO: 6814) (FURUNO, Head office: Nishinomiya, Hyogo Prefecture, President: Yukio Furuno) have developed a receiver for GPS and other global navigation satellite systems (GNSS), dramatically improving time-synchronization accuracy in areas with severe reception conditions such as among buildings and in mountainous areas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181029005364/en/
Satellite selection algorithm and GNSS receiver prototype performance test results (Graphic: Business Wire)
By integrating a new satellite signal selection algorithm developed by NTT into a time synchronization GNSS receiver from FURUNO, in addition to signals from satellites in line-of-sight locations, it has become possible to use multi-path signals (reflected or diffracted from buildings and other structures), which previously inhibited accuracy of time synchronization. In a real multi-path reception test environment, time error was reduced to approximately 1/5 of earlier values. This is a remarkable result in that it promises to enable time synchronization accuracy close to that obtained in open-sky reception environments with no obstructions, even in environments previously considered poor and unsuitable for accurate time synchronization, such as among buildings or in mountainous areas.
FURUNO plans to begin sales of their new GF-88 series time synchronization GNSS receivers incorporating this new technology in April of 2019, and to deploy it widely in fields such as 4G/5G mobile base stations, financial trading, power grids, and data centers.
We plan to exhibit these results at Tsukuba Forum 2018 *1 on October 25 and 26 (https://www.tsukuba-forum.jp/e/index.html), and at ITSF 2018 *2 , in Bucharest, Romania on November 5 to 8 (http://itsf2018.executiveindustryevents.com).
For details, please visit the following URLs:
http://www.ntt.co.jp/news2018/1810e/181023a.html
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=728&dispmid=961
| Reference/Terminology descriptions | ||
| *1 | Tsukuba Forum 2018 | |
| The largest general symposium on various technologies related to access networks in Japan, held by NTT. | ||
| *2 | The International Timing & Sync Forum (ITSF) 2018 | |
| The largest conference in the world on the theme of network timing and synchronization, covering fields including communications, finance, energy, transport, broadcast and defense. | ||
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005364/en/
Contact information
For inquiries regarding this article
Nippon Telegraph and Telephone
Corporation
Information Network Laboratory Group, Planning
Department, Public Relations Office
inlg-pr-pb-ml@hco.ntt.co.jp
or
FURUNO
ELECTRIC CO., LTD.
Mr. Kazushi Yamada
Management Planning &
Intelligence Dept., Public Relations Office
kazushi.yamada.dg@furuno.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 22:30:00 EEST | Press release
Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 21:45:00 EEST | Press release
Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of European enterprises, providing a framework for high performance in even the most complex, secure environments. “With about 6 million developers across Europe, users deserve infrastructure that meets them where they are,” said Varun Mohan, CEO of Windsurf. “The demand for secure AI-powered development is undeniable and by launching this GPU cluster, we aim to b
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 20:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization journey, allowing developers to focus on building engaging games, not commerce infrastructure. This SDK connects three
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 18:00:00 EEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom